![Walter Dettling](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Walter Dettling
Presidente presso Inotech Biotechnologies AG
Profilo
Walter Dettling is currently the Chairman at Inotech Biotechnologies AG since 2009.
He was previously a Director at Vivendy Therapeutics Ltd.
from 2013 to 2014.
Posizioni attive di Walter Dettling
Società | Posizione | Inizio |
---|---|---|
Inotech Biotechnologies AG
![]() Inotech Biotechnologies AG Pharmaceuticals: MajorHealth Technology Inotech Biotechnologies AG specializes in research, development and production of biopharmaceuticals products. It helps people by creating apps and gadgets to reach their health and fitness goals. The company is headquartered in Basel, Switzerland. | Presidente | 04/12/2009 |
Precedenti posizioni note di Walter Dettling
Società | Posizione | Fine |
---|---|---|
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Direttore/Membro del Consiglio | 10/03/2014 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Inotech Biotechnologies AG
![]() Inotech Biotechnologies AG Pharmaceuticals: MajorHealth Technology Inotech Biotechnologies AG specializes in research, development and production of biopharmaceuticals products. It helps people by creating apps and gadgets to reach their health and fitness goals. The company is headquartered in Basel, Switzerland. | Health Technology |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Health Services |
- Borsa valori
- Insiders
- Walter Dettling